News & Views

Thursday 16th May 2013 09:35

Britain will use G8 to aid dementia research

Britain and the United States have agreed to launch a joint programme to develop drugs to treat the condition.

During a visit to New York today, the Prime Minister will say that hundreds of thousands of elderly people live with conditions such as Alzheimer’s without receiving help to alleviate its symptoms.

Government sources said the PM was pushing to increase diagnosis rates to 67 per cent by 2015. The current rate is 45 per cent. There are estimated to be 670,000 people in England suffering dementia, of whom 350,000 remain undiagnosed, without support.

Mr Cameron will warn that the condition is fast becoming the biggest source of pressure on care systems around the world. There are thought to be 35.6 million people worldwide living with dementia, but the number is projected to soar to 65.7 million in 2030 and 115.4 million in 2050. A G8 dementia summit will be held in London in September, bringing together health and science ministers with medical and pharmaceutical experts.

Mr Cameron said last night: “Dementia is a devastating disease – not just for sufferers but for their families and friends too. And as more people live longer, it is fast becoming one of the biggest social and healthcare challenges we face. Families, communities, health systems and their budgets will increasingly be strained as the number affected increases and so we need to do all we can to improve how we research, diagnose and treat the disease.”

The Health Secretary, Jeremy Hunt, added: “For too long diagnosis rates have been shockingly low, leaving too many people living in the dark trying to cope with this terrible condition undiagnosed, unable to get the help they need.

“Dementia is a serious and growing problem so this ambitious drive to see a clear majority of people identified and supported is a major step forward.”

Disclaimer

The information on this site is intended only for the use of Independent Financial Advisors (IFAs) and other professionally recognised financial intermediaries & institutions.. Should you proceed to access this site, you will be representing and warranting that you are an IFA or other professionally recognised financial intermediary . What follows is not an offer or invitation to acquire an investment and should therefore not be relied upon by, any person in any jurisdiction where such an offer or invitation would be unlawful. Persons in respect of whom such prohibitions apply must not access this web site. None of the information contained on this site constitutes personal recommendations nor advice. Product details should always be read in conjunction with the appropriate offering documents. An application for any of the investment products on this page should be made having fully read not only the relevant application form, but also the relevant terms and conditions and offering documents. If you are unsure about the meaning of any information provided on this web page, then please consult your financial or other professional adviser. We do not offer investment advice.

This web site may contain or be linked to advice or statements of third parties. We make no representation as to the accuracy, completeness, timeliness or suitability of such information, and we have not and will not review or update such information and caution you that any use made of such information is at your own risk. Some of the information contained on this web site may also have been prepared or provided by third parties and may not have been verified by us. We hereby exclude any liability arising out of any preparation or provision of such information for the web site and makes no warranty as to the accuracy, suitability or completeness of any such information.

I agree, Continue

Information on this webpage relates to and is provided by Montreux Capital Management (UK) Limited

The content of this webpage should not be construed as financial advice. Any decision to invest should be made only on the basis of the relevant documentation for each investment. Past performance is not necessarily a guide to future performance. The value of an investment may go down as well as up and investors may not get back the full amount invested. Investments in small unquoted companies carry an above-average level of risk. These investments are highly illiquid and as such, there may not be a readily available market to sell such an investment. Montreux Capital Management (UK) Limited and Sapia Partners LLP (together "the Sponsors," or "Sponsor) do not provide specific individual advice on the suitability of investments with regard to a potential investor's individual circumstances, risk tolerance or investment objectives and investors should seek independent financial advice if they are in any doubt whether a product is suitable for them.

Montreux Capital Management (UK) Limited is an Appointed Representative of Sapia Partners LLP which is authorised and regulated by the Financial Conduct Authority.

I agree, Continue